Are there antibody-drug conjugates approved for Neuroendocrine Tumors

Antibody-Drug Conjugates for Neuroendocrine Tumors

Based on the current NCCN Guidelines for Neuroendocrine and Adrenal Tumors (Version 3.2025), there are no antibody-drug conjugates (ADCs) that are currently FDA-approved specifically for neuroendocrine tumors (NETs).

What This Means

Antibody-drug conjugates are a type of targeted therapy that combines an antibody (which recognizes specific proteins on cancer cells) with a chemotherapy drug. The antibody acts like a "guided missile," delivering the chemotherapy directly to cancer cells while sparing healthy tissue.

While ADCs have shown promise in other cancer types, they are not yet part of the standard treatment recommendations for NETs according to the NCCN Guidelines.

Current Approved Treatments for NETs

According to NCCN Guidelines, the main systemic therapy options for advanced NETs include:

• Somatostatin analogs (octreotide LAR, lanreotide) - for symptom control and tumor growth
• Peptide receptor radionuclide therapy (PRRT) with lutetium Lu 177 dotatate - for SSTR-positive tumors
• Targeted therapies: Everolimus, sunitinib (pancreatic NETs), cabozantinib
• Chemotherapy: Temozolomide, platinum-based regimens (cisplatin/etoposide), oxaliplatin-based combinations
• Immunotherapy: Pembrolizumab (for specific molecular profiles like MSI-H or TMB-H)

Questions to Ask Your Oncologist

1. Are there any clinical trials testing antibody-drug conjugates for my specific type of NET?
2. Which of the approved treatments would be most appropriate for my tumor's characteristics?
3. Are there any emerging therapies I should know about?
4. Would I be a candidate for a clinical trial?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.